Abiomed Announces Several Reimbursement Milestones

Mon Mar 4, 2013 8:00am EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130304:nGNXUXHCAa

* Four Commercial Insurers Institute Broad Impella Coverage
* Impella Economic Study Published in The Journal of Managed Care Medicine (JMCM)

DANVERS, Mass., March 4, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc
http://www.globenewswire.com/newsroom/ctr?d=10023807&l=1&a=Abiomed%2C%20Inc&u=http%3A%2F%2Fwww.abiomed.com%2F
. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today provided a
reimbursement update. Abiomed announced several recent Impella coverage decisions from national
payers including Humana, UnitedHealthcare, Independence Blue Cross and Capital BlueCross. The
recently updated coverage decisions include new Impella policies in the payers' commercial and/or
Medicare Advantage plans.

Additionally, an economic study on the use of percutaneous ventricular assist devices (pVAD) was
published in the February edition of The Journal of Managed Care Medicine (JMCM), "A Budget Impact
Model to Estimate the Cost Dynamics of Treating High-Risk Heart Failure Patients with Advanced
Percutaneous Cardiac Assist Devices: The Payer Perspective."

The study developed a Budget Impact Model (BIM) to estimate the annual direct medical costs of
treatment and the combined incremental budget impact of introducing a pVAD treatment option. A BIM
is a standard approach used by most commercial payers today to assess impact on their spend per
member. The study concluded that the per-member per-month (PMPM) impact of the use of pVADS in
very challenging patient populations was minimal throughout the technology adoption curve and that
patients did not require expensive readmissions for hospital care.

"In this era of healthcare reform, these models help identify the most effective and efficient
ways to manage patients, particularly patients with the potential to generate significant costs if
not managed properly," said David Gregory, MPA, FACHE, author of the study and Executive Vice
President and Partner, Presscott Associates - A Division of ParenteBeard, LLC.

"New clinical guidelines, coupled with clinical and economic studies like this, are all paving the
way for Impella to become the new standard of care," said Michael R. Minogue, Chairman, President
and Chief Executive Officer of Abiomed

Data for this study were obtained from a nationally-recognized database compiled by OptumInsight,
Inc. (Eden Prairie, MN) comprising claims generated by a national commercial health plan
consisting of approximately 25 million members. This model tracked patients for a full year
subsequent to the initial hospital stay.

The Journal of Managed Care Medicine(JMCM) is the official publication of National Association of
Managed Care Physicians (NAMCP). The mission of NAMCP is to improve patient outcomes by providing
educational material, evidence-based tools and resources to medical directors from purchasers,
plans and provider systems. The JMCM article can be viewed online at:
http://www.namcp.org/journals/jmcm/articles/16-1/budget_impact.pdf
http://www.globenewswire.com/newsroom/ctr?d=10023807&l=7&u=http%3A%2F%2Fwww.namcp.org%2Fjournals%2Fjmcm%2Farticles%2F16-1%2Fbudget_impact.pdf


ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that
provide circulatory support. Our products are designed to enable the heart to rest by improving
blood flow and/or performing the pumping of the heart. For additional information please visit:
www.abiomed.com
http://www.globenewswire.com/newsroom/ctr?d=10023807&l=9&a=www.abiomed.com&u=http%3A%2F%2Fwww.abiomed.com%2F


The Abiomed logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13564
http://www.globenewswire.com/newsroom/ctr?d=10023807&l=10&u=http%3A%2F%2Fwww.globenewswire.com%2Fnewsroom%2Fprs%2F%3Fpkgid%3D13564


FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including statements regarding development of
Abiomed's existing and new products, the Company's progress toward commercial growth, and future
opportunities and expected regulatory approvals. The Company's actual results may differ
materially from those anticipated in these forward-looking statements based upon a number of
factors, including uncertainties associated with development, testing and related regulatory
approvals, including the potential for future losses, complex manufacturing, high quality
requirements, dependence on limited sources of supply, competition, technological change,
government regulation, litigation matters, future capital needs and uncertainty of additional
financing, and other risks and challenges detailed in the Company's filings with the Securities
and Exchange Commission, including the most recently filed Annual Report on Form 10-K and
quarterly report on Form 10-Q. Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this release. The Company
undertakes no obligation to publicly release the results of any revisions to these forward-looking
statements that may be made to reflect events or circumstances that occur after the date of this
release or to reflect the occurrence of unanticipated events.

CONTACT: Susie Lisa, CFA
         Senior Director, Investor Relations and Corporate Development
         978-646-1590
         slisa@abiomed.com
         
         Aimee Genzler
         Corporate Communications Manager
         978-646-1553
         ir@abiomed.com

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.